A $216 billion market is being built around the idea that your body is a broken machine and you need expensive gadgets to fix it. That number should excite you and scare you in equal measure. The biohacking boom is real, it’s accelerating, and most people buying into it have no idea what they’re actually paying for.
According to a new report from Astute Analytica, the global biohacking market is on track to hit US$216.68 billion by 2035, powered by metabolic monitoring, wearable diagnostics, and personalized health optimization. That’s not a niche wellness trend anymore. That’s an industry. A big, loud, well-funded industry with a lot of people who want to sell you a continuous glucose monitor you probably don’t need.
The Body as a Data Problem
Here’s the pitch biohacking sells: your body is constantly producing data, and you’re just not reading it. Slap on a wearable, track your sleep cycles, monitor your HRV, measure your ketones, and suddenly you’re not just living — you’re optimizing. It sounds rational. It sounds scientific. And for a small percentage of people, it genuinely is.
For everyone else, it’s expensive anxiety in a subscription box.
The metabolic monitoring category alone is exploding. CGMs — continuous glucose monitors — were designed for diabetics managing a serious medical condition. Now they’re being marketed to healthy people who want to see how their oat milk latte spikes their blood sugar. The data is real. The clinical context, for most users, is not.
Who’s Actually Benefiting Here?
Let’s be honest about the power dynamic. The people who benefit most from biohacking right now aren’t the weekend warriors tracking their VO2 max. They’re the founders and VCs who figured out that attaching the word “personalized” to any health product doubles its price point. They’re the companies who’ve worked out that selling you a dashboard for your own biology creates an almost unbreakable subscription loop. You can’t unlearn your data. Once you know your resting heart rate trends, you keep checking.
This isn’t entirely cynical. Wearable diagnostics have done genuinely useful things. The Apple Watch has detected atrial fibrillation in people who had no idea they had it. Continuous sleep tracking has helped people with chronic fatigue find patterns their doctors missed. Real people have made real changes based on real data. That part of the story matters.
But the market doesn’t stop there. The market pushes into nootropics with sketchy evidence bases. It sells infrared saunas, peptide stacks, and cold plunge tubs to people who could walk around the block more often and see the same results. The signal gets buried in the noise because the noise is more profitable.
The Hot Take
Most biohacking isn’t science — it’s cosplay for people who find conventional self-improvement too boring. Wearing a $500 ring to track your sleep stages is less about health optimization and more about performing wellness to yourself and your group chat. The data gives you permission to feel like you’re doing something without actually changing anything. If the biohacking industry actually worked at scale, it would shrink. The fact that it’s growing to a quarter of a trillion dollars tells you everything about what it’s really selling.
The Part That Does Matter
Strip away the supplements and the influencer stacks and there’s a kernel of something genuinely important here. Personalized medicine is not a gimmick. The idea that a single dietary guideline or sleep recommendation applies equally to every human being is increasingly indefensible. We differ genetically, microbiologically, hormonally. Tailoring health interventions to the individual isn’t woo — it’s where serious medicine is heading.
The tech that underpins biohacking — the sensors, the AI-driven pattern recognition, the real-time biomarker monitoring — that technology is going to matter enormously in clinical settings. The same tools being used to sell overpriced wellness kits to tech workers in San Francisco will eventually be used to catch metabolic disease earlier in populations that actually need intervention. That transition is where the real value is.
You can draw a straight line from this boom to other sectors being reshaped by biological data and consumer tech crossover. The same forces driving biohacking adoption are pushing markets like lab-grown meat onto mainstream plates and rethinking how we interact with digital and physical systems at a fundamental level. The consumer appetite for control over biological outcomes is driving investment across every category that touches the human body.
Where This Heads Next
The next five years will determine whether biohacking matures into something clinically meaningful or collapses into a wellness bubble. Regulation will be the deciding factor. The FDA is watching CGM marketing closely. The FTC has started paying attention to supplement claims. And as AI-driven health platforms get more sophisticated — some already operating with the kind of data ambition you’d associate with companies like those competing in high-stakes tech power struggles — the question of who owns your health data becomes urgent fast.
The $216 billion number isn’t the story. The story is what happens when an industry built on self-quantification meets the hard wall of evidence-based medicine. Some of it will survive that collision and become something genuinely useful. The rest will end up in the same drawer as your Fitbit from 2015.